Allarity Therapeutics, Inc. Common Stock
ALLRAllarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment. The company specializes in identifying targeted therapies based on tumor biology and genetic profiles to improve patient outcomes. Previously known as Oncothyreon Inc., Allarity aims to advance its pipeline through research and partnerships in oncology.
Company News
Allarity Therapeutics reported significant progress with stenoparib, receiving FDA Fast Track designation for advanced ovarian cancer and presenting clinical trial data showing median overall survival exceeding 25 months for patients receiving the drug twice daily.
Allarity Therapeutics presented promising Phase 2 clinical trial data for stenoparib, a dual PARP and WNT pathway inhibitor for advanced ovarian cancer. The study showed median overall survival exceeding 25 months, with potential benefits for patients with different genetic backgrounds.
Allarity Therapeutics' CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London, discussing stenoparib, a novel dual PARP and WNT pathway inhibitor for cancer treatment, and the company's DRP® companion diagnostic platform.
Allarity Therapeutics signed a non-exclusive licensing agreement with an undisclosed EU-based biotechnology company, providing access to proprietary DRP® algorithms in breast cancer and laboratory services, which validates their drug response prediction technology.
Allarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.
